Powered by its Artificial Intelligence Platform, HMNC Brain Health is addressing an urgent medical need by personalizing the treatment of neuropsychiatric disorders.

Genetic tests in combination with treatment are already a common protocol in other medical areas, such as oncology, but are still a novelty in psychiatry.

HMNC Brain Health develops patented genetic tests together with world-leading scientists from the Max Planck Institute, and combines those with innovative medications, resulting in Targeted and Personalized Therapeutics for Major Depressive Disorder (MDD) and Treatment Resistant Depression (TRD).

The unique HMNC Brain Health precision psychiatry approach, based on IP protected companion diagnostics powered by artificial intelligence, enhances patient outcomes by leveraging the efficacy of commonly described antidepressants and proprietary novel therapeutic compounds.

As a result, patients benefit from earlier onset of effect and higher remission rates, as well as reduced side effects. Thanks to the prevention of non-effective therapies and due to shorter disability periods and hospitalizations, the health care systems can realize immense cost savings.